Trial Profile
A global phase III clinical trial of Bevacizumab Biosimilar (CT-P16)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
- 29 Aug 2018 New trial record
- 10 Aug 2018 According to a Celltrion media release, the company has ubmitted its Clinical Trial Application for Phase 3 clinical study to the National Authority of Medicines and Health Products, I.P. (Infarmed) of Portugal.